Provided by Tiger Trade Technology Pte. Ltd.

Senti Biosciences, Inc.

1.20
+0.03002.56%
Post-market: 1.18-0.0195-1.62%19:59 EST
Volume:473.94K
Turnover:562.04K
Market Cap:31.39M
PE:-0.40
High:1.21
Open:1.19
Low:1.16
Close:1.17
52wk High:5.10
52wk Low:1.15
Shares:26.16M
Float Shares:9.58M
Volume Ratio:0.56
T/O Rate:4.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9839
EPS(LYR):-12.0350
ROE:-394.62%
ROA:-67.77%
PB:3.87
PE(LYR):-0.10

Loading ...

Senti Biosciences Grants Stock Options to New Employee

Reuters
·
Dec 19

Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating

MT Newswires Live
·
Dec 10

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 10

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Benzinga_recent_news
·
Dec 10

Senti Biosciences (SNTI.US) Surges Over 7% at Open on Positive Phase 1 SENTI-202 Trial Data

Stock News
·
Dec 09

Senti Biosciences Reports Promising Clinical Results for SENTI-202 in AML Trial

Reuters
·
Dec 09

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Senti-202 in the Treatment of Adults With Relapsed or Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
Dec 09

Senti Biosciences Initiated at Outperform by Leerink Partners

Dow Jones
·
Nov 21

Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment

TIPRANKS
·
Nov 21

Senti Biosciences Q3 Net Income USD -18.126 Million

Reuters
·
Nov 20

Cell therapy developer Senti Biosciences' Q3 net loss narrows

Reuters
·
Nov 14

BRIEF-Senti Biosciences Q3 Net Income USD -18.126 Million

Reuters
·
Nov 14

Senti Biosciences Q3 EPS USD -0.69

THOMSON REUTERS
·
Nov 14

Press Release: Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Dow Jones
·
Nov 14

BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart

Reuters
·
Oct 15

BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes

Reuters
·
Oct 14

Senti Biosciences Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 14

HC Wainwright Initiates Coverage on Senti Biosciences With Buy Rating, $12 Price Target

MT Newswires Live
·
Oct 14

Senti Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Oct 14

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing the Phase 2 Dose and Schedule Selection for Senti-202 in Its Clinical Trial for Acute Myeloid Leukemia

THOMSON REUTERS
·
Aug 12